Update shared on27 Aug 2025
Fair value Increased 5.02%Analysts have raised MannKind’s price target to $9.71, citing the accretive acquisition of scPharmaceuticals, which expands and diversifies MannKind’s addressable market and growth prospects despite recent negative sentiment around earnings.
Analyst Commentary
- Bullish analysts see the acquisition of scPharmaceuticals as adding a high-growth, large-market asset that diversifies MannKind's revenue base.
- The acquisition price/multiple for scPharmaceuticals is considered attractive and reasonable by bullish analysts.
- The deal is expected to provide MannKind with access to a total addressable market of approximately $13B.
- Bullish analysts believe market reaction to MannKind's Q2 earnings was overly negative, overlooking growth drivers such as Afrezza pediatric uptake and the advancing MNKD-101 and MNKD-201 pipeline.
- Bearish analysts covering scPharmaceuticals do not expect alternative bidders and attribute their downgrade to the definitive nature of the acquisition agreement.
What's in the News
- H.C. Wainwright reiterated a Buy rating on MannKind with a $9 price target, viewing the scPharmaceuticals acquisition as positive for revenue diversification and noting the deal price was "very reasonable" (H.C. Wainwright, 2025-08-25).
- MannKind completed a $200 million private placement of senior secured term loans with Blackstone Alternative Credit Advisors, raising $75 million immediately and securing an additional $125 million in commitments, with a floating interest rate and a five-year maturity (Key Development, 2025-08-06).
- MannKind was dropped from multiple Russell indices—including the Russell 2000, 2500, 3000, and Microcap Value and Growth indices—on June 28 and June 30, 2025 (Key Development, 2025-06-28, 2025-06-30).
- MannKind presented results from its INHALE-1 pediatric clinical trial for Afrezza inhaled insulin at the American Diabetes Association's 85th Scientific Sessions, and expects to submit a supplemental Biologics License Application in mid-2025 for pediatric use (Key Development, 2025-06-09).
- MannKind showcased advances in inhaled insulin treatment for children and adolescents and highlighted upcoming topline results from its INHALE-1 study expected in Q2 2025 (Key Development, 2025-06-09).
Valuation Changes
Summary of Valuation Changes for MannKind
- The Consensus Analyst Price Target has risen from $9.25 to $9.71.
- The Future P/E for MannKind has significantly risen from 54.53x to 62.28x.
- The Net Profit Margin for MannKind has fallen from 17.28% to 16.17%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.